Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAIRI-guided individualized adjuvant therapy in locally advanced nasopharyngeal carcinoma (Phase III)
ChiCTR2500112850Phase 3Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of capecitabine in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 3-year Failure-Free Survival (FFS). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
capecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2500112850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112850.